Juno Therapeutics Inc (NASDAQ:JUNO) shares were up 6.3% during mid-day trading on Tuesday . The stock traded as high as $31.45 and last traded at $31.17, with a volume of 1,596,736 shares traded. The stock had previously closed at $29.32.

Several research analysts have recently issued reports on JUNO shares. Zacks Investment Research upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a report on Monday, April 18th. JPMorgan Chase & Co. lowered shares of Juno Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $63.00 to $39.00 in a research report on Friday, July 8th. FBR & Co reiterated a “buy” rating on shares of Juno Therapeutics in a research report on Tuesday, May 10th. Cowen and Company reiterated a “buy” rating and set a $55.00 target price on shares of Juno Therapeutics in a research report on Sunday, July 10th. Finally, Morgan Stanley lifted their target price on shares of Juno Therapeutics from $48.00 to $50.00 in a research report on Friday, April 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $54.19.

The stock has a 50-day moving average price of $37.58 and a 200 day moving average price of $37.41. The company’s market cap is $3.09 billion.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.26. The firm earned $9.80 million during the quarter, compared to analysts’ expectations of $4.83 million. During the same quarter in the previous year, the company posted ($0.30) EPS. Equities research analysts anticipate that Juno Therapeutics Inc will post ($2.28) EPS for the current fiscal year.

In related news, Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The shares were sold at an average price of $40.00, for a total value of $480,000.00. Following the transaction, the director now directly owns 858,799 shares in the company, valued at $34,351,960. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Bernard J. Cassidy sold 3,116 shares of the company’s stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $39.03, for a total transaction of $121,617.48. Following the completion of the transaction, the general counsel now owns 55,511 shares in the company, valued at $2,166,594.33. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently bought and sold shares of JUNO. US Bancorp DE boosted its position in Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock valued at $3,900,000 after buying an additional 1,600 shares during the period. BNP Paribas Arbitrage SA boosted its position in Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 10,884 shares during the period. BBR Partners LLC bought a new position in Juno Therapeutics during the fourth quarter valued at $1,539,000. Swiss National Bank bought a new position in Juno Therapeutics during the fourth quarter valued at $2,603,000. Finally, California Public Employees Retirement System boosted its position in Juno Therapeutics by 878.7% in the fourth quarter. California Public Employees Retirement System now owns 105,700 shares of the biopharmaceutical company’s stock valued at $4,648,000 after buying an additional 94,900 shares during the period.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.